The American Federal Medicines Agency (FDA) confirms the efficacy of Pfizer vaccine to prevent covid infections in children between the ages of 5 and 11. The FDA posted the results of its analysis on Pfizer’s serum overnight, ahead of a meeting scheduled for next week to discuss whether to give the green light to vaccination of some 28 million American children.
In the study, the agency concludes that in almost all scenarios the benefits of the vaccine in preventing hospitalization and death outweigh any side effects. If the FDA clears immunization with Pfizer, the Centers for Disease Control and Prevention a few days later will make their recommendations as to who will receive the doses in the first week of November.
Yesterday, the company said their vaccine showed 90.7% effectiveness against the coronavirus in a clinical study involving children between the ages of 5 and 11. Children under 12 involved in the trial received a dose of 10 micrograms, one third lower than that given to older populations (30 micrograms). According to the results submitted by the manufacturers to the FDA, the dosage was shown to be safe and the reported side effects were mild. Of the 2,268 children recruited, double the proportion of the placebo group received the vaccine. In the control group, 16 children contracted Covid, while among the vaccinated, 3 became ill: an efficacy of over 90%.